Business Context and Reporting Period
Company: National Research Corporation (NRC Health)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2002
Business Overview: The Company provides healthcare survey services and operates an automated software process for survey creation and processing.
Key Financial Metrics
| Metric | Q1 2002 | Q1 2001 |
|---|---|---|
| Revenues | $4,048,627 | $4,090,543 |
| Net Income | $294,400 | $503,133 |
| Operating Income | $575,804 | $744,753 |
| Operating Margin | 14.3% | 18.2% |
| Net Cash from Operating Activities | $916,453 | $1,071,068 |
| Cash and Cash Equivalents (End of Period) | $1,232,568 | $2,672,591 |
| Working Capital | $7,921,691 | N/A |
| Total Debt (Notes Payable) | $5,276,033 | N/A |
Note: Total Debt includes current portion ($128,082) and long-term portion ($5,147,951) as of March 31, 2002.
Material Changes vs. Prior Period
- Revenue: Essentially flat, decreasing slightly by 1.0% compared to Q1 2001.
- Profitability: Net income declined 41.5% to $294,400. Operating income decreased 22.7% to $575,804.
- Expense Trends:
- Direct Expenses: Decreased 9.8% due to lower labor and fieldwork costs, improving the direct expense ratio to 44.3% of revenue.
- Selling, General & Administrative (SG&A): Increased 33.6% to $1.27 million, driven by higher salaries, legal/consulting fees, and product development. SG&A rose to 31.4% of revenue.
- Other Income/Expense: Shifted from a net gain of $17,571 in 2001 to a net expense of $108,162 in 2002. This was primarily due to $63,731 in prejudgment interest recorded related to a resolved lawsuit.
- Cash Flow: Operating cash flow decreased 14.5% to $916,453, attributed to lower net income and changes in working capital (increases in receivables and decreases in deferred revenue).
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Expense Outlook: Management expects direct expenses to remain at similar or slightly higher levels for the balance of 2002. SG&A expenses are expected to decrease to the lower 20% range of revenue for the remainder of the year.
- Tax Rate: The effective tax rate for the rest of 2002 is expected to remain similar to the Q1 2002 level of 37.0%.
- Other Income: The significant interest expense related to the lawsuit is considered a one-time item; other income/expense is expected to trend toward prior year levels.
Risks and Contingencies
- Legal Proceedings: A lawsuit filed by Cap Gemini America, Inc. was resolved in February 2002 with a jury verdict ordering the Company to pay approximately $700,000. The Company had previously accrued $800,000. The settlement resulted in a reduction of capitalized software assets and direct expenses, along with the recording of prejudgment interest.
- Accounting Changes: The Company adopted SFAS No. 142 effective January 1, 2002, ceasing the amortization of goodwill and certain intangible assets. No impairment loss was recognized upon adoption.
Investor Verification Checklist
- Legal Settlement Impact: Verify the final cash outflow and asset write-downs associated with the Cap Gemini lawsuit settlement.
- SG&A Sustainability: Confirm if the elevated SG&A expenses (31.4% of revenue) are temporary or indicative of a structural cost increase.
- Deferred Revenue: Monitor the $2.58 million in "billings in excess of revenues earned" to ensure timely recognition in future quarters.
- Stock Repurchases: Track progress on the authorized repurchase of 150,000 shares (56,700 repurchased as of May 3, 2002).
- Goodwill Valuation: Review future impairment testing results for the $7.9 million in goodwill and intangible assets under the new SFAS No. 142 standard.